In the recent past, it was impossible to even consider the use of psychedelics in modern medicine. Throughout the 20th century, psychedelics such as LSD and psilocybin were a forbidden topic. The banning of these compounds in the United States began in the 1960s and restrictions scaled from there. Eventually, the majority of these hallucinogens were named Schedule I drugs and punishment for possession was not to be taken lightly.
However, as science (and society) have progressed, there’s been a slow and steady adoption of plant and fungi medicine into the medical system, particularly the mental health sphere. As Michael Pollan said in his article, The Trip Treatment, “As the drug war subsides, scientists are eager to reconsider the therapeutic potential of these drugs, beginning with psilocybin.”
Now, half a century after psychedelics were first declared illegal, they’re beginning to make a comeback with legalization on the state level in various cities around the country. In fact, the FDA and DEA are starting to approve psychedelic studies and allow researchers to examine the effects of the natural compounds on mental illness. This is a time many thought would never come.
The mental health crisis is worse than we thought
The fact that we are seeing greater use of psychedelics in mental health is monumental, especially as the mental illness epidemic continues to sweep our globe. Right now, over 700 million people suffer from this unspoken epidemic – including anxiety, depression, PTSD, substance abuse and beyond. In fact, the global cost of depression is valued at a monumental $1T.
The impact is devastating, from breaking families apart to suicide to poverty and more. Mental health statistics have only been exacerbated by the COVID-19 pandemic. With widespread social isolation, the loss of jobs and homes, and deaths of loved ones, cases have skyrocketed. There was a 20% increase in the use of antidepressant and anti-anxiety drugs in the U.S. during the COVID-19 quarantine. Additionally, the rate of depressive disorders quadrupled in the 2nd quarter of 2019.
The medical sphere is coming to terms with the fact that we need better solutions. Common treatments used for these chronic conditions are outdated and not effective in providing sufficient support or long-term relief. Believe it or not, the non-adherence rate to antidepressants is 75%, meaning that the medication either doesn’t work or has a negative impact on the patient. And, nearly one-third of patients with Major Depressive Disorder (MDD) are treatment-resistant while 50-66% of patients on antidepressants do not fully recover.
It’s time for something better – a solution that provides people with the relief they need to thrive. And for the 700 million people suffering worldwide, that can’t come soon enough. This is where natural medicine steps in.
More and more research shows that psychedelics like psilocybin mushrooms and LSD could be effective in helping people who suffer from chronic mental health conditions. In 2018, the FDA granted “breakthrough therapy” status to psilocybin mushrooms, referring to clinical trials for the fungi to aid patients suffering from treatment-resistant depression. Due to the increasing need for innovation in the mental health sphere and growing social acceptance of psychedelics, more time and money is being put into psychedelic research for mental illness as it proves a promising solution to a growing epidemic.
Non-synthetic medicines prove promising
In a medical environment that prioritizes synthetic drugs, patients might not have access to natural and effective solutions for years to come. Fortunately, Ei.Ventures (Emotional Intelligence Ventures) is determined to shift this dismal projection. Stemming from a passion for creating natural, non-synthetic remedies for the vast number of people suffering from chronic mental health conditions, Ei.Ventures is developing botanical psychedelic therapeutics and nutraceuticals.
In a study of 2000 individuals, it was discovered that 1 in 2 people avoid traditional medicine in favor of natural alternatives because synthetic medications simply aren’t doing the trick. Ei.Ventures takes the stance in the “farma vs. pharma” debate that whole-plant medicines can be more impactful than the synthetics commonly prescribed. They believe that their non-synthetic compounds can offer patients true, long-term relief with minimal side effects. In a medical community that has rejected natural remedies up until recent years, this cutting-edge startup has the opportunity to create big waves.
Ei.Ventures offers a suite of mental wellness products and services designed for the prevention, reversal, and management of a variety of chronic mental health disorders. Their first project is named Psilly, a transdermal patch that administers a low-dose, psilocybin-based formulation. This proprietary formulation combines high-quality psilocybin extract with other natural and complementary plant extracts. The high-tech patches are designed to make treatment significantly more convenient than other methods. This is because the patch allows the medicine to pass through the blood-brain barrier and bypass the gastrointestinal tract, providing direct delivery of active ingredients to the body. The benefits include improved patient well-being, a quick onset with consistent drug levels, and minimal side effects.
Ei.Ventures has also developed several functional mushroom nootropics composed of psychedelic compounds made from whole botanical extracts. These products have been formulated for a variety of indicators, including cognition and immune system, energy and vitality, mood, sleep, weight loss, mental and physical optimization, and joint and muscle pain. The company’s unique formulation process allows for these nootropics to have enhanced bioavailability and greater efficacy.
The last branch of development includes telepsychiatry and wellness app partnerships. As a company that emphasizes a natural approach over pharmaceutical prescriptions as the first step to intervention, the company seeks to facilitate greater availability of telehealth to those in need of support.
The psychedelic pharmaceutical boom is just beginning
These areas of product development come together to represent a $34.5B industry. This groundbreaking startup is stepping into an environment rich with opportunity. Plus, there hasn’t been another time in history when people have needed effective mental health solutions more.
Additionally, Ei.Ventures has the early mover’s advantage for several reasons: Mental health conditions have been rising since COVID-19, big pharma companies like Johnson & Johnson are starting to develop psychedelic mental health treatments, and psychoactive pharmaceuticals are in the infancy stage with a high barrier to entry.
The startup is presenting a promising opportunity to invest in psychedelic medicine. They already have a foot in the door with a leadership team that holds a strong clinical, FDA, and botanical drug development background and an experienced advisory board of thought leaders spanning multiple disciplines. They also hold a robust library of intellectual property consisting of both psychedelic and non-psychoactive compounds, and an immediate go-to-market strategy that combines FDA drug pipeline development with alternative legal pathways to bring their solutions to the market.
Their products are currently in the pre-clinical and pre-manufacturing phase of development, and they’re aiming to provide early access to the patients who need these innovative solutions the most. The company plans to achieve commercialization and licensing beginning with Psilly, advance into phase 2 trials within 18 to 24 months, achieve full FDA approval, launch their medicinal mushroom formulas into the $250B nutraceutical market, and license their proprietary formulas to other organizations. They’re also aiming to expand their unique telepsychiatry app to compliment their products for a full spectrum approach.
Ei.Ventures recently signed an LOI with Mycotopia Therapies Inc., a biopharma company focused on the development of medical psychedelics. When a definitive agreement is reached, Mycotopia will acquire Ei.Ventures by Q1 of 2022 and merge to become PSLY.COM, a $360 Million transaction with plans to list on NASDAQ. As a joint venture, they will focus on developing fungi and plant-based psychedelic solutions. Their main goals include completing preclinical and phase 1 trials to launch Psilly into legal jurisdictions and acquire a Drug Master File with the FDA so that they can sell their formulations while protecting their IP.
And, under this new name, the company just purchased virtual land estate in The Sandbox, an online world where players can trade NFTs through the Sandbox marketplace. In partnership with Orthogonal Thinker, PSLY.COM will make it possible for clinicians to virtually host psychedelic therapy sessions in the metaverse. Although these plans are in their early stages, they believe that this land deal will lead the way for billions of people to receive virtual access to psychedelic therapy.
This is just the tip of the iceberg when it comes to the mental health renaissance.
Here’s how you can join the mental health revolution
As medicine starts to turn back to the natural world and society begins to see the merit in the earth’s unaltered plant medicine, we can understand how potent these natural compounds are. Ei.Ventures is offering an investment opportunity of a lifetime as they are getting a headstart in the medicine revolution that’s quickly gaining traction. This is your opportunity to get in on the ground floor. Invest in Ei.Ventures today.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AT: